Novartis Japan Man Reportedly To Be Indicted For Falsifying Diovan Data
This article was originally published in PharmAsia News
Executive Summary
The former Novartis Japanese employee behind alleged manipulation of clinical trial data of its Diovan (valsartan) hypertension drug reportedly is expected to be indicted on charges of violating the nation's Pharmaceutical Affairs Law.